Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients


CAKIRCA M., KARATOPRAK C., ZORLU M., KISKAC M., Kanat M. , CIKRIKCIOGLU M. A. , ...More

DRUG DESIGN DEVELOPMENT AND THERAPY, vol.8, pp.239-243, 2014 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 8
  • Publication Date: 2014
  • Doi Number: 10.2147/dddt.s52545
  • Title of Journal : DRUG DESIGN DEVELOPMENT AND THERAPY
  • Page Numbers: pp.239-243

Abstract

Aims: A close association has been demonstrated between increased cardiovascular risk and high asymmetric dimethylarginine (ADMA) levels in type 2 diabetes mellitus (DM) patients. We planned to measure serum ADMA levels in type 2 DM patients using vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor.